Sulfasalazine (SASP) has been commonly used in the maintenance treatment for inflammatory bowel disease (IBD), including ulcerative colitis and Crohn's disease, and for rheumatoid disease. SASP is split into sulfapyridine (SP) and 5-aminosalicylic acid (5-ASA) components by bacterial azo reductases in the colon and caecum, followed by acetylation of SP into N-acetylsulfapyridine (AcSP) by polymorphic N-acetyltransferase 2 (NAT2) [EC 2.3.1.5] in the liver.
N-Acetyltransferase 2 Genotype-Related Sulfapyridine Acetylation and Its Adverse Events
Sulfapyridine (SP), one of the metabolites of sulfasalazine (SASP), is further metabolized into N-acetylsulfapyridine (AcSP) by polymorphic N-acetyltransferase 2 (NAT2). NAT2 activity has been diagnosed by phenotyping, that is, evaluating plasma concentrations or urinary excretions of tentatively administered test drugs for dose individualization and avoidance of serious adverse events. Herein, we investigated the relationship between NAT2 genotypes and the pharmacokinetics of SP in healthy Japanese subjects, as well as the adverse events of SASP in patients with inflammatory bowel disease (IBD). Eight healthy subjects and 13 IBD patients were classified into three groups by NAT2 genotyping; the homozygote for the wild-type allele (Rapid Types), the compound heterozygote for the wild-type and mutant alleles (Intermediate Types), and the homozygote for mutant alleles (Slow Types). A single oral dose of 40 mg/kg SASP was administered to each healthy subject, and plasma and urine samples were taken until 51 and 72 h after administration, respectively. Both the SP and AcSP concentrations in each sample were determined by the HPLC method. The NAT2 genotypes were well-correlated with the plasma concentrations or urinary excretions of SP and AcSP in 8 healthy subjects, except for one Slow Type. In patients with IBD, skin rash was seen in 3 of 6 Rapid Types and 1 of 6 Intermediate Types, consistent with the concept that hypersensitive reactions are independent of serum SP concentrations. In contrast, SASP dosing-related acute pancreatitis was found in the Slow Type patient. In this case, the NAT2 activity was diagnosed by genotyping in advance, and the medical staff could pay scrupulous attention, resulting in no serious subjective symptoms such as abdominal pain, anorexia or fever. Further investigations on the relationship between the NAT2 genotype and adverse events are required, although genotyping appeared to be a promising method to avoid such serious adverse events.
based on the wild-type allele (NAT2*4) or three mutant alleles (NAT2*5B, NAT2*6A and NAT2*7B), which were determined by the PCR-RFLP method as described previously. [11] [12] [13] The NAT2 genotypes in 8 healthy subjects were NAT2*4/*4 (nϭ3), NAT2*4/*6A (nϭ2), NAT2*4/*7B (nϭ1), NAT2*6A/*7B (nϭ1) and NAT2*7B/*7B (nϭ1), and those of 13 patients were NAT2*4/*4 (nϭ6), NAT2*4/*6A (nϭ3), NAT2*4/*7B (nϭ3) and NAT2*6A/*7B (nϭ1). NAT2 genotypes were classified into three groups; Rapid Types (NAT2*4/*4), Intermediate Types (NAT2*4/*6A and NAT2*4/*7B), and Slow Types (NAT2*6A/*7B and NAT2*7B/*7B). It is noted that the terms of "Type" mean those defined by NAT2 genotyping. The aims of this study were fully explained to each subject, and written informed consent was obtained.
Pharmacokinetics of SP and AcSP after Single Oral Administration of SASP in Healthy Subjects Eight nonsmoker subjects (age: 23-32 years, 6 male and 2 female) participated in the SASP administration study. Each subject received a single oral dose of SASP (40 mg/kg, 2.41Ϯ0.40 g (meanϮS.D.)) as a non-enteric coated Salazopirin ® tablet (WelFide Co., Osaka, Japan) after breakfast. They were prohibited to take any drugs for one week prior to SASP administration until the final urine sampling. Blood samples were drawn at 4, 8, 12, 16, 27, 31, 37 and 51 h after SASP administration, and were immediately centrifuged at 3000 rpm (950ϫg) for 5 min to separate the plasma samples. Urine samples were also collected every 3 h up to 72 h after SASP administration. Each blank sample for the assay reference was obtained on the day before the SASP administration. Both plasma and urine samples were stored at Ϫ20°C until assay of the SP and AcSP concentrations. It was confirmed that there was no alteration of the concentrations by freezing.
Determination of SP and AcSP SP and AcSP concentrations in the plasma and urine samples were measured by HPLC as described previously. [13] [14] [15] [16] HPLC (LC-6A series, Shimadzu Co., Kyoto, Japan) consisted of a system controller (SCL-6B, Shimadzu), a variable wavelength ultraviolet detector (SPD-6AV, Shimadzu) adjusted to 260 nm, and a data processor (Chromatopac C-R4A, Shimadzu). The stationary phase was a reversed phase Chemcobond 5-ODS-H column (4.6 mm i.d.ϫ250 mm, particle size 5 mm, Chemco Chemical Co., Ltd., Osaka, Japan). The mobile phase was 20 mM phosphate buffer containing 0.1% tetrabutylammonium hydrogen sulphate : methanol (77.5 : 22.5, v/v). The flow rate was 1.0 ml/min and the column temperature was maintained at 40°C. The calibration curves were linear over a concentration range of 0.5 to 50.0 mg/ml (r 2 Ͼ0.994) for SP and 0.2 to 50.0 mg/ml (r 2 Ͼ0.994) for AcSP. Pharmacokinetic and Statistical Analysis The area under the plasma concentration-time curve and the mean residence time in the body of SP and AcSP (AUC SP , AUC AcSP , MRT SP and MRT AcSP , respectively) were calculated using the plasma concentrations of SP and AcSP until 51 h by the linear trapezoidal method. The mean acetylation time (MAcT) was estimated as MRT AcSP ϪMRT SP to give the index of the rate of acetylation.
The values presented are meansϮS.D. Statistical analyses were performed using an unpaired t-test. Statistical significance was set at pϽ0.05.
Adverse Events in Patients with IBD Thirteen patients (age: 26-63 years, 7 male and 6 female) had taken a nonenteric coated Salazopirin ® tablet (WelFide Co.) as the maintenance treatment for IBD; 12 of them had ulcerative colitis and one had Crohn's disease. The dosing regimen of SASP and concomitant drugs, the clinical characteristics of each patient, and adverse events were obtained from clinical records. Figure 1 shows the plasma concentration curves of SP and AcSP after a single oral administration of SASP in 8 healthy subjects. The plasma concentrations of AcSP were much higher than SP in Rapid Types (subject Nos. 1-3), and concentrations of both SP and AcSP showed similar curves in Intermediate Types (subject Nos. [4] [5] [6] and also in one of two Slow Types (subject No. 8). As for the other Slow Type (subject No. 7), plasma concentrations of SP were much higher than AcSP. The AUC SP and AUC AcSP values showed substantial inter-individual variability, however, their AUC ratios (AUC AcSP / AUC SP ) were correlated with the three genetically defined groups with one exception, subject No. 8 (Table 1) . The MRT SP and MRT AcSP showed similar values, however, MAcT showed substantial variability. MAcT was longest in subject No. 8.
RESULTS

Pharmacokinetics of SP and AcSP after Single Oral Administration of SASP in Healthy Subjects
The cumulative urinary excretion patterns of SP and AcSP corresponded to plasma concentration curves (Fig. 2) . The urinary excretion of AcSP was much higher than SP in Rapid Types, and urinary excretion of both SP and AcSP was similar in Intermediate Types and also in one of two Slow Types (subject No. 8). In contrast, the urinary excretion of SP was significantly higher than AcSP in another Slow Type (subject No. 7). In Fig. 3 , the urinary recovery ratios of AcSP/SP were also related to AUC.
Adverse Events in Patients with IBD The characteristics of the 13 patients with IBD are summarized in Table 2.   1060 Vol. 25, No. 8
Fig. 2. Cumulative Urinary Excretion versus Time Curves for SP (᭹) and AcSP (᭺) Following a Single Oral Administration of SASP in 8 Healthy Subjects
The urinary excretion of AcSP is presented as equivalent to SP. All patients showed normal hepatic and renal functions. Six patients were co-administered prednisolone (patient Nos. 1-4, 6 and 13). Skin rashes were seen in 4 patients: in 3 of 6 subjects (50%) in Rapid Types (patient Nos. 4-6) and 1 of 6 subjects (17%) in Intermediate Types (patient No. 11). Acute pancreatitis was seen in 1 of 1 subject (100%) in the Slow Type (patient No. 13). Figure 4 shows the clinical records of patient No. 13, who showed acute pancreatitis. After the hospitalization, the administration of 4 g/d SASP was begun as the treatment for ulcerative colitis on June 26th. The 0.3 g/d of isoniazid (Sumifon ® tablets (Sumitomo Pharmaceuticals Co., Ltd. (Osaka, Japan))) and 1 g/d of panipenem (Carbenin ® injection (Sankyo Pharmaceuticals Co. Ltd. (Tokyo, Japan))) were also administered with SASP as the treatment for tuberculosis. After that, serum lipase and amylase were elevated gradually to 1,761 IU/l (normal level: Ͻ129 IU/l) and 448 IU/l (normal level: 65-185 IU/l) on July 31. The amylase isozyme was Ptype dominant and maintained high levels of 246-363 IU/l (normal level: 32-100 IU/l) during the SASP administra- tion. However, neither subjective symptoms such as abdominal pain and anorexia, nor objective signs such as fever, skin rash, or abdominal tenderness were observed. All these clinical test values decreased gradually after stopping SASP administration on August 11th; however, they increased again by the re-administration of SASP from August 23rd to September 5th, because of a relapse.
DISCUSSION
In 8 healthy subjects studied, we found a good correlation between NAT2 genotypes and the pharmacokinetics of SP and AcSP/SP ratios in healthy subjects, except in one Slow Type (subject No. 8). In subject No. 8, MAcT was the longest among the subjects, suggesting the slowest rate of acetylation of SP (Table 1) . When isoniazid was administered to subject No. 8, he also showed the slowest acetylation of isoniazid into its acetylated metabolite.
11) The individual variability of the bacterial azo reductase activity must affect the production and absorption rate of SP. SP was hydroxylated into 5Ј-OHsulfapyridine by an unknown polymorphic metabolizing enzyme, [17] [18] [19] and then into glucuronide by polymorphic UDP glycosyltransferase. 20) Thus, this discrepancy might be explained by the slow degradation rate of SASP or the complicated metabolic pathways of SP. It is important to recognize that NAT2 genotyping sometimes fails to diagnose NAT2 activity, presumably depending on the metabolic pathway of the drugs, or some other factors. Deguchi et al. also suggested that the predictability of this genotyping was 93-97.5%. Recently, Parkin et al. suggested 14 mutations on the NAT2 gene. The sophisticated classification of the patients based on these mutations might explain the discrepancy related above.
Skin rashes were seen in 50% of the Rapid Types and in 17% of the Intermediate Types, consistent with the theory that the hypersensitive reactions are independent of serum SP concentrations (Table 2) . A skin rash during SASP administration is understood to be essentially unpredictable, and occurs at the initiation of therapy. 7, 9) In contrast, acute pancreatitis was observed after the treatment with a high dose (4 g/d) of SASP (Fig. 4) . Mild pancreatitis was also found after the administration of a low dose (0.5 g/d) of SASP, both suggesting this adverse event is due to SASP. However, concurrently administered isoniazid was also acetylated by NAT2 and known to induce pancreatitis; 21) thus, further investigations are needed on the relationship between NAT2 genotype and SASP-induced pancreatitis. In this case, the NAT2 activity was diagnosed by genotyping in advance, and medical staff could pay scrupulous attention, resulting in no serious subjective symptoms such as abdominal pain, anorexia or fever. Further investigations on the relationship between the NAT2 genotype and adverse events are required, although genotyping appeared to be a promising method for avoiding serious adverse events.
In conclusion, the NAT2 genotyping can be a useful method to predict the pharmacokinetic properties of SASP and to avoid serious adverse events when SASP is scheduled for administration.
